Pfizer/BioNTech, Moderna Vaccines & Regeneron mAbs Hold Up to New York SARS-CoV-2 Variant

PfizerBioNTech, Moderna Vaccines & Regeneron mAbs Hold Up to New York SARS-CoV-2 Variant

A New York City research team led by scientists from NYU’s Grossman School of Medicine, co-authored by Nathaniel Landau, wanted to better understand if the Pfizer/BioNTech and Moderna vaccines, as well as the monoclonal antibody cocktail from Regeneron Pharmaceuticals, could neutralize a prominent SARS-CoV-2 variant circling around New York now known as the B.1.526 variant. Spreading around the region at alarming rates, the variant has two versions that have been identified both inclusive of the D614G mutation in the spike protein combined with four new point mutations and includes an E484K or S477N mutation in the receptor binding domain, triggering concern that this could dilute the efficacy of the vaccines and therapies. According to this recent study, the results “show that this potential problem is not going to be a problem,” quotes Landau.

After exposing replicas of the New York variants to blood from those who have received either Moderna’s mRNA-1273 or Pfizer’s BNT162b2 or the Regeneron monoclonal antibody cocktail, the researchers discovered that the vaccine treatments were “very effective at binding the altered spike protein.” The researchers also found that the Regeneron therapy continues to be “a potent blocker” of the virus.

Lead Research/Investigator

Responses